

# Carbohydrate-Functionalized Triazolylidene Iridium Complexes: Hydrogenation Catalysis in Water with Asymmetric Induction

Joseph P. Byrne,<sup>[a, b]</sup> Lidia Delgado,<sup>[c]</sup> Francesca Paradisi,<sup>[a, c]</sup> and Martin Albrecht<sup>\*[a]</sup>

Two sets of carbohydrate-NHC hybrid iridium complexes were synthesised in order to combine properties of carbohydrates and triazolylidene (trz) ligands in organometallic catalysis. One set features a direct trz linkage to the anomeric carbohydrate carbon, while the second set is comprised of an ethyl linker between the two functional units. Deprotection of the carbohydrate afforded hybrid complexes that efficiently catalyse the direct hydrogenation of ketones in water. The catalytic activity

of the hybrid complexes was influenced by the pH of the aqueous medium and surpassed the activity of carbohydrate-free or acetyl-protected analogues (>90% vs 13% yield). While no enantiomeric induction was observed for the ethyl-linked hybrids, a moderate enantiomeric excess (*ee*) was induced by the directly linked systems. Moreover, these carbohydrate-trz hybrid complexes displayed mixed inhibitory activity towards a glycosidase from *H. orenii* that contain a glucose binding site.

## Introduction

Carbohydrates constitute an attractive class of compounds for the functionalization of homogeneous catalysts since they impart high water solubility and offer a natural and highly diverse pool for introducing chirality. Remarkably carbohydrates are considerably underexploited in catalysis when compared to other natural chiral pools such as amino acids.<sup>[1,2]</sup> Pioneering work involving carbohydrate incorporation into phosphine and phosphinite ligands has demonstrated, however, promisingly high enantioselectivities in catalytic olefin hydrogenation.<sup>[3–10]</sup>

Carbohydrate functionalisation of NHC ligands has been developed only recently,<sup>[11]</sup> with the majority of research thus far focused towards imidazolylidene ligands and their saturated analogues. Carbohydrate–NHC hybrid complexes have shown anticancer activity,<sup>[12]</sup> and catalytic activity in Ru-catalysed olefin metathesis reactions,<sup>[13]</sup> Ir-catalysed alcohol and amine oxidation,<sup>[14]</sup> and Pd-catalysed Suzuki–Miyaura coupling,<sup>[15–17]</sup> as well as in Rh-catalysed carbohydrate-directed asymmetric hydrosilylation of ketones.<sup>[18,19]</sup> Notably, these applications involved fully protected carbohydrate derivatives, and only in Suzuki–Miyaura coupling, in situ deprotection under catalytic conditions has been assumed.<sup>[16,17]</sup> Our group recently demonstrated that carbohydrate-trz iridium complexes (trz = 1,2,3-triazol-5-ylidene) were sufficiently robust to be deprotected at the carbohydrate site, and that deprotection significantly enhanced the catalytic activity in alcohol and amine oxidation.<sup>[14,20]</sup>


The installation of deprotected carbohydrate functionalities on organometallic complexes offers several opportunities. For example, increased solubility in aqueous media allows for using water as a safe, cheap, and abundant solvent<sup>[21,22]</sup> with the potential to regulate activity through pH modifications, although stability of organometallic systems in buffer solutions is not yet commonplace.<sup>[23]</sup> These properties paired with sufficiently robust complexes have been exploited to couple organometallic catalysis in tandem with enzymatic transformations,<sup>[24–29]</sup> and to build artificial metalloenzymes upon docking of organometallic entities to proteins.<sup>[30–32]</sup> Similar applications may emerge from carbohydrate-organometallic hybrid systems, since biological receptors for specific carbohydrate bonding are well known, and indeed, carbohydrate-functionalised triazoles were shown to inhibit the activity of glycosidases.<sup>[33,34]</sup>


Here we demonstrate the incorporation of a variety of carbohydrate motifs into Ir-triazolylidene complexes, and their marked impact on catalytic ketone hydrogenation catalysis,


[a] Dr. J. P. Byrne, Prof. F. Paradisi, Prof. M. Albrecht  
 Departement für Chemie  
 Biochemie und Pharmazie  
 Universität Bern  
 Freiestrasse 3  
 3012 Bern (Switzerland)  
 E-mail: martin.albrecht@unibe.ch  
 Homepage: <https://albrecht.dcbp.unibe.ch>

[b] Dr. J. P. Byrne  
 Present address  
 School of Chemistry  
 National University of Ireland Galway  
 University Road  
 Galway H91 TK33 (Ireland)

[c] L. Delgado, Prof. F. Paradisi  
 School of Chemistry  
 University of Nottingham  
 University Park  
 Nottingham NG7 2RD (UK)

 Supporting information for this article is available on the WWW under <https://doi.org/10.1002/cctc.202200086>

 This publication is part of a joint Special Collection with EurJOC on "Carbohydrate Chemistry". Please check the ChemCatChem homepage for more articles in the collection.

 © 2022 The Authors. ChemCatChem published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

both in terms of activity as well as stereoselectivity. Specifically, the anomeric position was identified to be key for inducing *S*- vs *R*-entio-preference of the catalyst. Furthermore, bonding of the carbohydrate-trz hybrid complexes to glucose hydrolase was probed to establish the impact of the protein on catalysis.

## Results and Discussion

### Synthesis of carbohydrate–triazolylidene iridium complexes.


Carbohydrate-functionalised triazoles **1** were prepared from phenylacetylene via copper-catalysed alkyne azide cycloaddition (CAAC) of the corresponding glucose-, galactose, and mannose-azides,<sup>[35–37]</sup> respectively (Scheme 1). Analogous triazoles **2** with an ethylene spacer between the triazole heterocycle and the carbohydrate unit were synthesized from the corresponding azidoethyl glycopyranosides, which were available via glycosylation of penta-*O*-acetylglycopyranose with bromoethanol and subsequent nucleophilic substitution with  $\text{NaN}_3$ .<sup>[38–40]</sup> All compounds **1–2** were obtained in good yields (41–78 %).<sup>[12,14,41]</sup>

A characteristic singlet at *ca.* 7.9 ppm in each  $^1\text{H}$  NMR spectrum confirmed formation of the triazole heterocycle. In all compounds, the triazole displayed a single set of  $^1\text{H}$  NMR resonances, confirming that the products did not undergo anomerisation. Specifically, the anomeric pair **1 $\alpha$ Man** and **1 $\beta$ Man**, display different  $^1\text{H}$  NMR spectra, with distinct coupling constants of the doublet resonance for the anomeric proton of 2.6 Hz (at 6.07 ppm) and 1.4 Hz (at 6.19 ppm), respectively. The resonances arising from the anomeric protons in triazoles **2** were significantly less deshielded than for **1** and, appeared around  $\delta_{\text{H}}$  4.5 with a  $^3J_{\text{H,H}}=7.8$  Hz coupling for **2 $\alpha$ Glc** and

**2 $\alpha$ Gal**, and 1.6 Hz for **2 $\beta$ Man**. Triazole **1 $\alpha$ Gal** was deprotected in excellent yields under Zémpfen conditions (SI),<sup>[33]</sup> but attempts to subsequently obtain the corresponding triazolium salt has failed in our hands. Protecting groups were therefore retained for the triazole alkylation and metalation steps.

Near-quantitative alkylation of **1–2** was achieved with  $[\text{Me}_3\text{O}]\text{BF}_4$  in  $\text{CH}_2\text{Cl}_2$  and confirmed by a diagnostic 0.5 ppm downfield shift of the  $\text{C}_{\text{trz}}\text{H}$  resonance in the  $^1\text{H}$  NMR spectrum of the triazolium salt **3** and **4** as well as by HRMS (ESI+) analysis. Reaction of **3–4** with  $\text{Ag}_2\text{O}$  and transmetalation with  $[\text{IrCl}_2(\text{Cp}^*)]_2$  afforded acetate-protected iridium(III) NHC complexes **5–6** in moderate yield (30–48%) after flash chromatography purification. These complexes were characterised by the absence of any downfield resonance in the  $^1\text{H}$  NMR spectrum and a diagnostic singlet at *ca.* 1.5 ppm corresponding to the  $\text{Cp}^*$  ligand. In **5 $\alpha$ Man** and **5 $\beta$ Man**, the  $^1\text{H}$  NMR resonances of the anomeric proton were broadened and also significantly deshielded by *ca.* 1 ppm with respect to **3 $\alpha$ Man** and **3 $\beta$ Man**, indicating electronic perturbation of this site upon metal coordination, similar to **5 $\beta$ Glc** and **5 $\beta$ Gal**.<sup>[14]</sup> By contrast, the resonances for the anomeric proton were essentially unchanged for **6** containing an ethylene spacer between the triazolylidene and carbohydrate moieties ( $\delta_{\text{H}}$  4.69–4.84), suggesting no electronic interaction between the carbohydrate and the Ir–triazolylidene unit.

Exposure of the complexes to methanolic  $\text{NaOMe}$ , *i.e.* typical acetyl deprotection conditions (*vide supra*), led to decomposition of iridium complexes **5**. Since triazolylidene iridium complexes are generally very stable under acidic conditions,<sup>[42]</sup> the acetyl protecting groups in complexes **5–6** were successfully removed with 0.5 M methanolic  $\text{HCl}$ .<sup>[14]</sup> Subsequent precipitation yielded the iridium complexes in



**Scheme 1.** Synthesis of carbohydrate-functionalized triazolylidene iridium complexes **7** and **8** and crystal structures of **5 $\beta$ Glc** and **7 $\beta$ Gal**. (50% probability, hydrogen atoms and  $\text{CH}_3\text{OH}$  molecules co-crystallised with **7 $\beta$ Gal** omitted for clarity).

good (**7**) to modest (**8**) yields as yellow solids that are air- and moisture stable for several months. The  $^1\text{H}$  NMR spectra ( $\text{CD}_3\text{OD}$ ) of all deprotected iridium complexes contained a single set of resonances, indicating that epimerization at the anomeric position does not occur under these deprotection conditions. All iridium complexes were analysed by a characteristic atomic mass corresponding to the  $[\text{M}-\text{Cl}]^+$  ion by HRMS (ESI+). Moreover, the structure of complex **7 $\beta$ Gal** was analysed by X-ray diffraction on single crystals grown upon diffusion of  $\text{Et}_2\text{O}$  into  $\text{CH}_3\text{OH}$  solution of the complex. The molecular structure confirms the  $\beta$ -configuration and chair conformation of the carbohydrate entity (Scheme 1). As expected for unprotected carbohydrates, the structure features a series of hydrogen bonding interactions between adjacent galactosyl units as well as to co-crystallized  $\text{MeOH}$  molecules (SI). No intramolecular hydrogen bonding was identified in the solid state. Bonding geometry about the iridium centre does not deviate significantly from related complex such as **7 $\beta$ Gal**,<sup>[14]</sup> or related complexes containing a simple triazolylidene ligand.<sup>[42]</sup>

**Interaction of **7 $\beta$ Gal** with molecular hydrogen.** In view of catalytic applications of these iridium complexes, their reactivity towards hydrogen was probed in aqueous solution ( $\text{H}_2\text{O}/\text{D}_2\text{O}$  9:1,  $40^\circ\text{C}$ ). Exposure of **7 $\beta$ Gal** to  $\text{H}_2$  induced a notable colour change from pale yellow to dark pink within 15 minutes. Analysis by  $^1\text{H}$  NMR spectroscopy revealed formation of a new complex which was characterized by a downfield shifted resonance for the  $\text{Cp}-\text{CH}_3$  groups ( $\Delta\delta$  ca. 1 ppm, Figure S.4a–b) and a broad resonance at  $\delta_{\text{H}} = -12.8$  integrating for two hydrogens. The spin lattice relaxation time of this latter high-field resonance,  $T_1 < 85$  ms,<sup>[43]</sup> suggests the formation of non-classical hydrides and a  $\text{Ir}-(\text{H}_2)$  complex rather than a classical dihydride.<sup>[44,45]</sup> This species was stable in solution under ambient conditions for several hours. When analogous experiments were carried out in  $\text{D}_2\text{O}$  solution, the same shift in the  $\text{Cp}^*$  signal was observed, but no high-field resonance was detectable. Instead, deuterium incorporation into the phenyl group of the triazolylidene ligand was observed by the disappearance of  $^1\text{H}$  resonances in the aromatic region of the  $^1\text{H}$  NMR spectrum (Figure S.4c–d). These data indicate H/D exchange of the hydride complex with solvent water and reversible cyclo-metallation of the phenyl group under these conditions.<sup>[46,47]</sup> We note that water is crucial as a solvent since no hydrogen complex was observed when the reaction was carried out in  $\text{CH}_2\text{Cl}_2$ ,  $\text{EtOH}$ , or  $\text{MeOH}$ . The carbohydrate functionality is obviously assisting in ensuring water solubility of the iridium complexes, though related unfunctionalized triazolylidene iridium complexes similarly form hydrides.<sup>[48]</sup> The ability of **7 $\beta$ Gal** to bind and activate hydrogen under atmospheric dihydrogen pressures prompts the use of this class of carbohydrate-functionalised NHC complex for application in direct hydrogenation catalysis in aqueous media.

**Ketone hydrogenation catalysis in aqueous conditions.** The catalytic activity of iridium complex **7 $\beta$ Gal** in ketone hydrogenation was assessed by saturating an aqueous solution at various pH with hydrogen gas for 15 minutes, *i.e.*, conditions that induce formation of the dihydrogen complex (*vide supra*). Subsequent addition of acetophenone as model substrate

induced quantitative conversion to 1-phenylethanol in less than 3 h ( $40^\circ\text{C}$ , 1 mol% **7 $\beta$ Gal**). Working in aqueous media offers opportunities to optimize the catalytic activity via pH modulation. Therefore, catalytic runs of **7 $\beta$ Gal** were conducted at different pH values using various buffer media (Table 1). Under neutral, and even more so under basic conditions, maximum yields were low, reaching only 18% and 35% yield at pH 8.0 and 7.4, respectively (entries 1,2). Precipitation of a yellow solid was also observed at basic pH after a few hours, tentatively attributed to the formation of insoluble hydroxide complexes. The catalytic performance improved considerably at acidic pH. At pH 5.8, yields reached 74% (entry 3), while further acidification to pH 5.0 gave 94% yield in 3 h and quantitative conversion after 4 h (entry 4). At pH 3.0, quantitative hydrogenation with **7 $\beta$ Gal** was accomplished already within 2 h (entry 5, Figure S5). Under these conditions, also lower catalyst loadings were active, though at 0.1 mol% **7 $\beta$ Gal**, conversions were incomplete even after 24 h and gave a maximum turnover number of 360. These data reveal a clear relationship between pH and both the reaction rate and final product yield, consistent with observations by Ogo *et al.*<sup>[49]</sup> with Ru-catalysed transfer hydrogenation. This behaviour may be rationalised by an increased stability of the hydride complex combined with substrate activation through proton bonding by the carbonyl group.<sup>[22,49]</sup>

While the well-defined stereochemistry of carbohydrates may induce asymmetric catalysis,<sup>[3,18,50–53]</sup> hydrogenation with **7 $\beta$ Gal** induced only a modest enantiomeric excess towards S-1-phenylethanol with slight variation upon pH modification. We note that the type of buffer, has a more significant impact on the modest but consistent enantiomeric enrichment of the 1-phenylethanol than the pH. Highest asymmetric induction (30% ee) was observed in citrate buffer, while unbuffered conditions (26% ee) were less effective, followed by phosphate (20% ee) and HEPES buffer (15% ee). This dependence suggests that the hydride stabilization by the buffer may be critical for enantio-discrimination of the substrate.

The impact of the carbohydrate functionality was probed under the optimised conditions, *viz.* citrate buffer at pH 3.0. The

**Table 1.** Catalytic acetophenone hydrogenation in aqueous solution buffered at various pH.<sup>[a]</sup>

Entry	Complex	pH	Buffer (50 mM)	Yield <sup>[b]</sup> [3 h; %]	e.e. [%] <sup>[c]</sup>
1	<b>7<math>\beta</math>Gal</b>	8.0	Phosphate	18 <sup>d</sup>	20 (S)
2	<b>7<math>\beta</math>Gal</b>	7.4	HEPES	35	15 (S)
3	<b>7<math>\beta</math>Gal</b>	5.8	Phosphate	74	21 (S)
4	<b>7<math>\beta</math>Gal</b>	5.0	Citrate	94	32 (S)
5	<b>7<math>\beta</math>Gal</b>	3.0	Citrate	> 98	30 (S)

[a] General conditions: acetophenone (0.1 mmol), Ir complex (1  $\mu\text{mol}$ , 1 mol%), aqueous buffer (1.0 mL); [b] determined by LCMS with phenol as internal standard; [c] determined by chiral GC; [d] yellow precipitate formed.

catalytic activity of **7βGlc**, **7βMan** and **7αMan** were highly similar to that of **7βGal** and reached >90% conversion within 2 h (Table 2 and Figure S6). Like **7βGal**, **7βGlc** and **7βMan** led to preferential formation of the *S*-enantiomer with 34% and 46%

Entry	Complex	Yield [2 h, %] <sup>[b]</sup>	e.e. [%] <sup>[c]</sup>
1	<b>7βGal</b>	98 (94)	30 ( <i>S</i> )
2	<b>7βGlc</b>	99 (94)	34 ( <i>S</i> )
3	<b>7βMan</b>	90 (86)	46 ( <i>S</i> )
4	<b>7αMan</b>	95 (99)	39 ( <i>R</i> )
5	<b>9</b>	13 (18)	<4
6	<b>5βGal</b>	70 (63)	45 ( <i>S</i> )
7	<b>5βGlc</b>	70 (66)	45 ( <i>S</i> )
8	<b>5βMan</b>	55 (69)	34 ( <i>S</i> )
9	<b>5αMan</b>	55 (65)	6 ( <i>S</i> )
10	<b>8βGal</b>	47 (40)	<4
11	<b>8βGlc</b>	59 (50)	<4
12	<b>8αMan</b>	47 (52)	<4

[a] general conditions: acetophenone (0.1 mmol), Ir complex (1 μmol, 1 mol%), citrate buffer (1.0 mL, 50 mM, pH 3.0), H<sub>2</sub> (1 atm.), 40 °C; [b] yields determined by HPLC relative to phenol as internal standard (in parentheses yields determined by <sup>1</sup>H NMR spectroscopy in CDCl<sub>3</sub> after product extraction, relative to anisole as internal standard); [c] determined by chiral GC.





Figure 1. Structure of simple triazolylidene complex **9**.

*ee*, respectively (entries 1–3). The same selectivity of **7βGal** and **7βGlc** suggests that the stereochemistry of the remote C-4 hydroxy group has negligible impact on the chirality transfer, while inversion at C-2 increases the asymmetric induction (**7βGal** vs **7βMan**). Remarkably, **7αMan** showed the opposite enantio-preference and favours the *R*-enantiomer (39% *ee*; entry 4). This outcome underscores that the NHC-linked carbohydrate scaffold is playing a pivotal role in substrate orientation for asymmetric hydrogen transfer, and that the anomeric configuration is decisive for *S*- vs *R*-preference.

A set of control experiments underpinned the pivotal role of the carbohydrate entity on both catalytic activity and asymmetric induction. Thus, catalytic hydrogenation reaction with **9**, a model iridium complex without carbohydrate functionality (Figure 1), gave very low yield and produced racemic product (Table 2, entry 5). Likewise, complexes **5** containing acetyl-protected carbohydrate units were considerably less active than the analogues with free carbohydrates and reached only 55–70% yield after 2 h (entries 6–9). Remarkably, the acetyl-protected complexes **5βGal** and **5βGlc** induce a higher enantiomeric excess (45%) than their deprotected analogues, while the effect is inverted for the mannose derivatives **5αMan** and **5βMan**. Furthermore, all protected carbohydrate-triazolylidene complexes showed a preference for the *S*-enantiomer, irrespective of the anomeric configuration.

In line with these trends, complexes **8** possessing an ethylene spacer between the deprotected carbohydrate and NHC units gave moderate yields of 47–59% in 2 h and no significant asymmetric induction (entries 10–12). The lack of *ee* is in agreement with the absence of any significant interaction between the carbohydrate and the triazolylidene entities as deduced also by NMR spectroscopy (*vide supra*).

A small substrate scope was carried out with **7βGal** as catalyst precursor (Scheme 2a). Acetophenones substituted



Scheme 2. Products formed by hydrogenation of various substrates. General reaction conditions: substrate (0.1 mmol), **7βGal** (1 μmol, 1 mol%), 1 atm. H<sub>2</sub>, 40 °C, citrate buffer (1.0 mL, 50 mM, pH 3.0); yields determined by <sup>1</sup>H NMR spectroscopy with anisole as internal standard after 2 h unless stated otherwise.



with electron-withdrawing nitro and electron-donating methoxy groups were converted with high yields, while an amine substituent impeded catalysis considerably. Cyclohexanone as a representative of aliphatic ketones and also bromobenzaldehyde were reduced under these conditions. Stilbene was inert, suggesting that olefins are not hydrogenated. However, activated olefins in  $\alpha,\beta$ -unsaturated ketones are converted as demonstrated with cinammyl ketone (Scheme 2b). Hydrogenation is considerably slower than with acetophenone with 38% conversion after 2 h and some selectivity towards the saturated ketone intermediate. This selectivity may be a consequence of predominant olefin reduction or efficient double bond migration.<sup>[54]</sup> Extension of the reaction time to 16 h yielded predominantly the fully reduced product.

**Interactions of iridium complexes with *H. orenii*  $\beta$ -glucosidase (GH1) enzyme.** Further tailoring of activity and selectivity was anticipated by embedding the catalytically active site within a biological scaffold. Specifically, we aimed at using the carbohydrate functionality in complexes 7–8 as anchoring group for interaction with  $\beta$ -glucosidase (GH1) enzyme from *H. orenii*, a thermophilic glycosidase containing an active site that is pre-organised to bind and hydrolyse O-linked  $\beta$ -glycopyranosides.<sup>[55]</sup>

Binding of various concentrations of complexes 7–8 was probed by monitoring the enzymatic rate of hydrolysis of *p*-nitrophenyl glucoside by a UV-Vis assay. Essentially complete inhibition (90–98%) was observed with all complexes at 0.5 mM concentration (Figure S43). Notably, model complex 9 without a carbohydrate functionality showed a similar level of inhibition, indicating that the loss of enzymatic activity is not limited to the competitive binding of the carbohydrate unit of complexes 7–8 to the GH1 active site.

Inhibition kinetic experiments were carried out for each complex, analysing the activity of the GH1 enzyme in the presence of 0.05 mM of each iridium complex 7–9. Variations in the reaction parameters with respect to the uninhibited enzyme (Table S2, ESI) indicate that all the complexes behave as ‘mixed inhibitors’, demonstrating a combination of competitive and non-competitive inhibition processes. Allosteric binding at sites other than the active carbohydrate-binding site is also occurring. Modelled as mixed inhibitors, dissociation constants for both processes were calculated. As expected for a  $\beta$ -glucosidase, the glucose-derived molecules, **7 $\beta$ Glc** and **8 $\beta$ Glc** ( $K_{ic}$  = 2.9(5) and 3.4(2)  $\mu$ M, respectively), have higher competitive affinity for the enzyme than the other examples, with **7 $\beta$ Glc** being *ca.* tenfold higher than the uncompetitive affinity.

Catalytic hydrogenation experiments with **7 $\beta$ Gal** in the presence of excess GH1 showed no detectable catalytic activity on acetophenone, suggesting that the lack of selective binding prevents these hybrid complexes from assembling into effective artificial metalloenzymes, and the catalyst active site is hindered. Indeed, in catalytic runs with 1 mM solutions of **7 $\beta$ Gal** and **7 $\beta$ Glc**, conversion of acetophenone was impacted already in the presence of only 0.3  $\mu$ M GH1 at pH 7.4 (HEPES 50 mM),<sup>[56]</sup> achieving about 20% and 15% yield, respectively, *i.e.*, half of the performance recorded in the absence of the enzyme (*cf.* Table 1). Interestingly, catalytic runs in the presence of non-

carbohydrate-binding protein BSA also stalled the activity of **7 $\beta$ Gal**, indicating a more general role of proteins to hinder this particular reaction. While catalysts 7–8 are bio-compatible and operate under physiologically relevant conditions in aqueous buffer solutions, translation of catalytic activity to biocatalysis through coupling with a protein scaffold still presents a significant challenge. In order to successfully exploit this bio-recognition, stronger and more specific protein-carbohydrate interactions with the carbohydrate-organometallic hybrid scaffold are required, such as, for example, those exhibited by lectins (e.g. Concanavalin A).<sup>[57]</sup> Multivalency, where multiple carbohydrate units are presented by a structure, are also well known to increase affinity of compounds for protein carbohydrate-receptor sites.<sup>[58]</sup> Moreover, variation of the iridium catalytic site, *e.g.* by chelate bonding might shield it from the protein environment to a greater extent and reduce inhibitive interactions.

## Conclusions

Carbohydrate-functionalised triazolylidene NHC iridium complexes are efficient pre-catalysts for ketone hydrogenation under mild aqueous conditions and low hydrogen pressures. They significantly outperform carbohydrate-free analogues and acetyl-protected analogues. Direct linkage of the carbohydrate motif to the NHC imparts much higher catalytic benefits compared to ethylene linked more remote carbohydrate trz hybrids. Under optimized conditions at low pH (citrate buffer at pH 3.0), these carbohydrate NHC systems gave essentially quantitative yields for hydrogenation of acetophenone within 2 h. While the carbohydrate entity induced only moderate enantiomeric enrichment up to ~50%, the enantioselectivity of the catalyst directly correlates with the stereochemistry at the anomeric carbohydrate position, which offers rational guidelines for further catalyst optimisations. Complexes 7–9 completely inhibited activity of glycosidase enzyme GH1 (*H. orenii*), acting as mixed inhibitors. Kinetic data showed that the glucose-derivatives has the highest competitive binding affinity for GH1, but hydrogenation catalysis was completely impeded by enzyme interactions. More efficient anchoring of the hybrid in the active site may provide a further approach to modulate and increase the catalytic activity and selectivity of these hybrid systems.

## Experimental Section

**General experimental details.** 1- $\alpha$ -azido-2,3,4,6-tetra-O-acetylmannopyranose was prepared by reaction of penta-O-acetylmannopyranose with TMSN<sub>3</sub> and SnCl<sub>4</sub><sup>[36]</sup> while the  $\beta$ -anomer was prepared *via* a glycosyl iodide.<sup>[37]</sup> 1-azidoethyl-2,3,4,6-tetra-O-acetylglycopyranosides,<sup>[38–40]</sup> **1Glc**,<sup>[14]</sup> **1Gal**,<sup>[14]</sup> **1 $\alpha$ Man**,<sup>[41]</sup> **2Man**,<sup>[41]</sup> **4Glc**,<sup>[14]</sup> **4Gal**,<sup>[14]</sup> [IrCl<sub>2</sub>Cp\*]<sub>2</sub>,<sup>[59]</sup> **5 $\beta$ Glc**,<sup>[14]</sup> **5 $\beta$ Gal**,<sup>[14]</sup> **7 $\beta$ Gal**,<sup>[14]</sup> **7 $\beta$ Glc**<sup>[14]</sup> and **9**<sup>[42]</sup> were prepared as described previously. Ag<sub>2</sub>O was used after regeneration by heating to >160 °C under vacuum. Dry, degassed solvents were obtained by filtering over columns of dried aluminium oxide under a positive pressure of argon. Other reagents were obtained from commercial suppliers and used as received.

NMR spectra were recorded on Bruker spectrometer operating at room temperature. Chemical shifts ( $\delta$  in ppm,  $J$  in Hz) were referenced to residual solvent resonances and are reported downfield from SiMe<sub>4</sub>. High resolution mass spectrometry and elemental analysis were performed by the Analytical Research Services at University of Bern.

Gas chromatography (GC) was performed on an Agilent 7820 A GC System using a CP-Chirasil-DEXC8 column (25 mm × 0.25 mm × 0.25  $\mu$ m) as stationary phase. LC analysis was carried out with an Agilent 1260 HPLC system, equipped with a reverse phase XBridge C18 (3.5  $\mu$ m, 2.1 mm × 30 mm) column, running a gradient method with 0.01 % aqueous ammonia and acetonitrile.

**Enzyme activity and inhibition assays.** In a 96-well plate, 10  $\mu$ L of enzyme solution, 90  $\mu$ L of inhibitor solution and 200  $\mu$ L of *p*-nitrophenyl glucoside solution were added together (to give final concentrations of [*p*-nitrophenyl glucoside] = 10 mM, [HEPES] = 50 mM, pH 7.4). Immediately upon mixing, the assay was begun and formation of *p*-nitrophenol monitored by measuring the formation of the absorbance at 420 nm over 10 minutes. Specific activity (U/mg) was expressed as  $\mu$ mol of product formed per minute per mg of protein. For inhibition studies [inhibitor] = 0–0.5 mM was used. For inhibition kinetics final concentration of [inhibitor] = 0.05 mM was used.

**Catalytic hydrogenation.** A 1.0 mM stock solution of the iridium complex was made up in aqueous buffer. 1.0 mL of this was transferred to a 10-mL round bottomed flask, before fitting with a rubber septum. The solution was saturated with H<sub>2</sub> for 15 minutes at 40 °C. Acetophenone (12  $\mu$ L, 0.10 mmol) was added and the reaction allowed to proceed under H<sub>2</sub> atmosphere.

To monitor the reaction by LC analysis, phenol was added as an internal standard before addition of ketone substrate, and the reaction sampled regularly by syringe. Chiral GC analysis samples were prepared from reactions without phenol and diluted in 2-propanol. In order to determine yield spectroscopically by <sup>1</sup>H NMR: after 2 h anisole (12  $\mu$ L, 0.11 mmol), as internal standard, and NaCl (0.3 g) were added, and the reaction mixture extracted (0.5 mL × 3) into CDCl<sub>3</sub>.

**Formation of iridium hydride species.** 7 $\beta$ Gal (5.0 mg, 0.007 mmol) was dissolved in a 9:1 mixture of deionized H<sub>2</sub>O and D<sub>2</sub>O and was bubbled with H<sub>2</sub> for 15 minutes at 40 °C. The <sup>1</sup>H NMR spectrum was measured at various temperatures under ambient conditions.

**General synthesis of triazoles.** The relevant protected azide precursor (1 equiv.), CuSO<sub>4</sub> · 5H<sub>2</sub>O (0.4 equiv.) and sodium ascorbate (1 equiv.) were dissolved in aqueous *tert*-butanol solution (1:1 mixture). To this, phenyl acetylene (1 equiv.) was added and (a) stirred at room temperature for 3 days, or (b) heated by microwave irradiation to 100 °C for 6 hours. Reaction mixture was extracted into CH<sub>2</sub>Cl<sub>2</sub> and washed with NH<sub>4</sub>Cl(aq) (×3), water (×2) and brine (×2), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure, yielding the triazole as a white or off-white solid. For 2Glc, 2Gal and 2Man, a precipitation from Et<sub>2</sub>O was necessary to purify the compound.

**1 $\beta$ Man.** According to the general procedure, 1- $\beta$ -azido-2,3,4,6-tetra-O-acetylmannopyranose (0.270 g, 0.73 mmol), CuSO<sub>4</sub> · 5H<sub>2</sub>O (0.073 g, 0.30 mmol), sodium ascorbate (0.146 g, 0.72 mmol) and phenylacetylene (0.08 mL, 0.73 mmol) were reacted. The crude solid was triturated with CH<sub>3</sub>OH and filtered, yielding 1 $\beta$ Man (0.240 g, 0.50 mmol, 70%). Anal. calc. for C<sub>22</sub>H<sub>25</sub>N<sub>3</sub>O<sub>9</sub> · CH<sub>3</sub>OH (507.498 g/mol), C 54.43, H 5.76, N 8.28%. Found C 54.18, H 6.29, N 8.31%; HRMS (ESI+) Calculated for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>9</sub><sup>+</sup> [M + H]<sup>+</sup>  $m/z$  = 476.1664. Found  $m/z$  = 476.1650; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 2.00 (s, 3H, OC(O)CH<sub>3</sub>), 2.05–2.19 (m, 9H, 3 × OC(O)CH<sub>3</sub>), 4.00 (ddd, 1H, <sup>3</sup>J<sub>H,H</sub> = 10.0,

6.2, 2.3 Hz, mannosyl C<sup>5</sup>H), 4.23 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 2.3 Hz, <sup>2</sup>J<sub>H,H</sub> = 12.5 Hz, mannosyl C<sup>6</sup>HH), 4.37 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 6.1 Hz, <sup>2</sup>J<sub>H,H</sub> = 12.5 Hz, mannosyl C<sup>6</sup>HH), 5.31 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 10.0, 3.1 Hz, mannosyl C<sup>3</sup>H), 5.38 (t, 1H, <sup>3</sup>J<sub>H,H</sub> = 10.0 Hz, mannosyl C<sup>4</sup>H), 5.80 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 3.1, 1.4 Hz, mannosyl C<sup>2</sup>H), 6.19 (d, 1H, <sup>3</sup>J<sub>H,H</sub> = 1.4 Hz, mannosyl C<sup>1</sup>H), 7.29–7.39 (m, 1H, C<sub>trz</sub>H), 7.40–7.60 (m, 2H, C<sub>ph</sub>H), 7.74–7.86 (m, 2H, C<sub>ph</sub>H), 7.99 (s, 1H, C<sub>trz</sub>H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 20.5, 20.6, 20.66, 20.74, (4 × OC(O)CH<sub>3</sub>), 62.3 (mannosyl C<sup>6</sup>H<sub>2</sub>), 65.0 (mannosyl C<sup>1</sup>H), 68.9 (mannosyl C<sup>2</sup>H), 70.8 (mannosyl C<sup>3</sup>H), 75.8, (mannosyl C<sup>5</sup>H), 84.8, (mannosyl C<sup>1</sup>H), 118.4, (C<sub>trz</sub>H), 125.8, 128.5, 128.9 (3 × C<sub>ph</sub>H), 130.1 (C<sub>ph</sub>–trz), 147.8 (C<sub>trz</sub>–Ph), 168.9, 169.6, 169.7, 170.5 (4 × C=O)

**2 $\beta$ Glc.** According to the general procedure, 1-azidoethyl-2,3,4,6-tetra-O-acetylglucopyranoside (0.950 g, 2.30 mmol), CuSO<sub>4</sub> · 5H<sub>2</sub>O (0.230 g, 0.92 mmol), sodium ascorbate (0.455 g, 2.30 mmol) and phenylacetylene (0.25 mL, 2.30 mmol) were reacted, yielding 2 $\beta$ Glc (0.680 g, 1.27 mmol, 55%). Anal. calc. for C<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O<sub>10</sub> · 0.5(H<sub>2</sub>O) · 0.5((C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>O) (519.509 g/mol), C 55.22, H 6.24, N 7.43%. Found C 55.48, H 6.75, N 7.54%; HRMS (ESI+) Calculated for C<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O<sub>10</sub>Na<sup>+</sup> [M + Na]<sup>+</sup>  $m/z$  = 542.1751. Found  $m/z$  = 542.1727; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.72, 1.98, 2.01, 2.07 (4 × s, 3H, OC(O)CH<sub>3</sub>), 3.69 (ddd, 1H, <sup>3</sup>J<sub>H,H</sub> = 9.5, 4.5, 2.5 Hz, glucosyl C<sup>5</sup>H), 3.91 (td, 1H, <sup>3</sup>J<sub>H,H</sub> = 2.5 Hz, <sup>2</sup>J<sub>H,H</sub> = 9.5 Hz, ethylene CHH), 4.13 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 2.5 Hz, <sup>2</sup>J<sub>H,H</sub> = 12.4 Hz, glucosyl C<sup>6</sup>HH), 4.21–4.33 (m, 2H, glucosyl C<sup>6</sup>HH and ethylene CHH), 4.46 (d, 1H, <sup>3</sup>J<sub>H,H</sub> = 7.8 Hz, glucosyl C<sup>1</sup>H), 4.49–4.75 (m, 2H, ethylene CH<sub>2</sub>), 4.97–5.25 (m, 3H, glucosyl C<sup>2</sup>H, C<sup>3</sup>H, C<sup>4</sup>H), 7.27–7.36 (m, 1H, C<sub>ph</sub>H), 7.37–7.49 (m, 2H, C<sub>ph</sub>H), 7.80–7.91 (m, 3H, C<sub>ph</sub>H and C<sub>trz</sub>H); <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD):  $\delta$  = 20.4, 20.59, 20.60, 20.7 (4 × OC(O)CH<sub>3</sub>), 50.1 (ethylene CH<sub>2</sub>), 61.7 (glucosyl C<sup>6</sup>H<sub>2</sub>), 67.9 (ethylene CH<sub>2</sub>), 68.2 (glucosyl C<sup>4</sup>H), 70.9 (glucosyl C<sup>2</sup>H), 72.0 (glucosyl C<sup>5</sup>H), 72.4 (glucosyl C<sup>3</sup>H), 100.5 (glucosyl C<sup>1</sup>H), 121.4 (C<sub>trz</sub>H), 125.7, 128.2, 128.8, 130.5 (4 × C<sub>ph</sub>), 147.6 (C<sub>trz</sub>–Ph), 169.4, 169.5, 170.1, 170.6 (4 × C=O).

**2 $\beta$ Gal.** According to the general procedure, 1-azidoethyl-2,3,4,6-tetra-O-acetylgalactopyranoside (2.03 g, 4.87 mmol), CuSO<sub>4</sub> · 5H<sub>2</sub>O (0.486 g, 1.95 mmol), sodium ascorbate (0.965 g, 4.87 mmol) and phenylacetylene (0.53 mL, 4.87 mmol) were reacted, yielding 2 $\beta$ Gal (1.100 g, 2.12 mmol, 43%). Anal. calc. for C<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O<sub>10</sub> · 0.5(H<sub>2</sub>O) · 0.5((C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>O) (519.509 g/mol), C 55.22, H 6.24, N 7.43%. Found C 55.45, H 6.66, N 7.30%; HRMS (ESI+) Calculated for C<sub>24</sub>H<sub>30</sub>N<sub>3</sub>O<sub>10</sub><sup>+</sup> [M + H]<sup>+</sup>  $m/z$  = 520.1926. Found  $m/z$  = 520.1937; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.70, 1.95, 2.04, 2.14 (4 × s, 3H, OC(O)CH<sub>3</sub>), 3.84–3.97 (m, 2H, galactosyl C<sup>5</sup>H and ethylene CHH), 4.01–4.20 (m, 2H, galactosyl C<sup>6</sup>H<sub>2</sub>), 4.29 (ddd, 1H, <sup>3</sup>J<sub>H,H</sub> = 4.2, 3.0 Hz, <sup>2</sup>J<sub>H,H</sub> = 10.1 Hz, ethylene CHH), 4.43 (d, 1H,  $J$  = 7.9 Hz, galactosyl C<sup>1</sup>H), 4.54 (ddd, 1H, <sup>3</sup>J<sub>H,H</sub> = 9.3, 3.0 Hz, <sup>2</sup>J<sub>H,H</sub> = 14.5 Hz, ethylene CHH), 4.69 (ddd, 1H, <sup>3</sup>J<sub>H,H</sub> = 4.2, 3.0 Hz, <sup>2</sup>J<sub>H,H</sub> = 14.5 Hz, ethylene CHH), 4.95 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 10.5, 3.5 Hz, galactosyl C<sup>3</sup>H), 5.21 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 10.5, 7.9 Hz, galactosyl C<sup>2</sup>H), 5.38 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 3.5, 1.1 Hz, galactosyl C<sup>4</sup>H), 7.27–7.36 (m, 1H, C<sub>ph</sub>H), 7.38–7.48 (m, 2H, C<sub>ph</sub>H), 7.79–7.93 (m, 3H, 2 × C<sub>ph</sub>H and C<sub>trz</sub>H); <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD):  $\delta$  = 20.47, 20.54, 20.66, 20.70 (4 × OC(O)CH<sub>3</sub>), 50.1 (ethylene CH<sub>2</sub>), 61.2 (galactosyl C<sup>6</sup>H<sub>2</sub>), 66.9 (galactosyl C<sup>4</sup>H), 67.8 (ethylene CH<sub>2</sub>), 68.5 (galactosyl C<sup>2</sup>H), 70.6 (galactosyl C<sup>3</sup>H), 70.8 (galactosyl C<sup>5</sup>H), 100.9 (galactosyl C<sup>1</sup>H), 121.6 (C<sub>trz</sub>H), 125.7, 128.1, 128.8, 130.5 (4 × C<sub>ph</sub>), 147.6 (C<sub>trz</sub>–Ph), 169.7, 170.0, 170.2, 170.4 (4 × C=O).

**General synthesis of triazolium salts.** The relevant triazole (1 equiv.) and Meerwein's reagent (Me<sub>3</sub>OBf<sub>4</sub>, 1.1 equiv.) were suspended in dry CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and stirred at room temperature for 18 hours. Reaction was quenched with CH<sub>3</sub>OH (0.5 mL) and concentrated under reduced pressure, yielding the product, which could be further purified by dissolving in a minimum of CH<sub>2</sub>Cl<sub>2</sub> and addition of copious diethyl ether, causing triazolium salts to precipitate as white solid in near-quantitative yields. These compounds were hygroscopic.

**3 $\alpha$ Man.** According to the general procedure, **1 $\alpha$ Man** (1.238 g, 2.60 mmol) and Meerwein's reagent (0.414 g, 2.80 mmol) were reacted, yielding **3 $\alpha$ Man** (1.550 g, quant.). HRMS (ESI<sup>+</sup>): Calculated for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>9</sub><sup>+</sup> [M-BF<sub>4</sub>]<sup>+</sup>  $m/z$  = 490.1820. Found  $m/z$  = 490.1799; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 2.04–2.12 (m, 9H, 3  $\times$  OC(O)CH<sub>3</sub>), 2.18 (s, 3H, OC(O)CH<sub>3</sub> [overlaps with acetone peak]), 4.07–4.56 (m, 6H, N-CH<sub>3</sub>, mannosyl C<sup>6</sup>H<sub>2</sub>, C<sup>5</sup>H), 5.35 (t, 1H, <sup>3</sup>J<sub>H,H</sub> = 8.0 Hz, mannosyl C<sup>4</sup>H), 5.56 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 8.0, 3.5 Hz, mannosyl C<sup>3</sup>H), 6.04 (t, 1H,  $J$  = 3.5 Hz, mannosyl C<sup>2</sup>H), 6.47 (d, 1H, <sup>3</sup>J<sub>H,H</sub> = 3.5 Hz, mannosyl C<sup>1</sup>H), 7.51–7.70 (m, 5H, C<sub>ph</sub>H), 8.57 (s, 1H, C<sub>trz</sub>H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 20.53, 20.55, 20.6, 20.69 (4  $\times$  OC(O)CH<sub>3</sub>), 39.2 (N-CH<sub>3</sub>), 61.2 (mannosyl C<sup>6</sup>H<sub>2</sub>), 65.2 (mannosyl C<sup>4</sup>H), 66.6 (mannosyl C<sup>3</sup>H), 68.4 (mannosyl C<sup>2</sup>H), 73.4 (mannosyl C<sup>5</sup>H), 87.4 (mannosyl C<sup>1</sup>H), 121.5 (C<sub>ph</sub>-trz), 128.4 (C<sub>trz</sub>H), 129.6, 129.7, 132.1 (3  $\times$  C<sub>ph</sub>H), 144.5 (C<sub>trz</sub>-Ph), 169.64, 169.65, 170.0, 170.9 (4  $\times$  C=O).

**3 $\beta$ Man.** According to the general procedure, **1 $\beta$ Man** (0.240 g, 0.46 mmol) and Meerwein's reagent (0.071 g, 0.48 mmol) were reacted, yielding **3 $\beta$ Man** (0.285 g, quant.). HRMS (ESI<sup>+</sup>): Calculated for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>9</sub><sup>+</sup> [M-BF<sub>4</sub>]<sup>+</sup>  $m/z$  = 490.1820. Found  $m/z$  = 490.1916; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 2.01, 2.12, 2.14, 2.16 (4  $\times$  s, 3H, OC(O)CH<sub>3</sub>), 4.18–4.38 (m, 6H, N-CH<sub>3</sub>, mannosyl C<sup>5</sup>H, C<sup>6</sup>H), 4.45 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 5.5 Hz, <sup>2</sup>J<sub>H,H</sub> = 12.9 Hz, mannosyl C<sup>6</sup>H), 5.37–5.55 (m, 2H, mannosyl C<sup>3</sup>H, C<sup>4</sup>H), 6.04 (app s, 1H, mannosyl C<sup>2</sup>H), 6.53 (app s, 1H, mannosyl C<sup>1</sup>H), 7.54–7.69 (m, 5H, C<sub>ph</sub>H), 8.51 (s, 1H, C<sub>trz</sub>H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  = 20.4, 20.5, 20.6, 20.7 (4  $\times$  OC(O)CH<sub>3</sub>), 39.0 (N-CH<sub>3</sub>), 61.6 (mannosyl C<sup>6</sup>H<sub>2</sub>), 64.6 (mannosyl C<sup>4</sup>H), 67.7 (mannosyl C<sup>2</sup>H), 70.8 (mannosyl C<sup>3</sup>H), 75.9 (mannosyl C<sup>5</sup>H), 86.5 (mannosyl C<sup>1</sup>H), 121.6 (C<sub>ph</sub>-trz), 127.5 (C<sub>trz</sub>H), 129.6, 129.8, 132.2 (3  $\times$  C<sub>ph</sub>H), 143.6 (C<sub>trz</sub>-Ph), 169.6, 169.7, 169.8, 170.8 (4  $\times$  C=O).

**4 $\beta$ Glc.** According to the general procedure, **2 $\beta$ Glc** (0.770 g, 1.50 mmol) and Meerwein's reagent (0.244 g, 1.65 mmol) were reacted, yielding **4 $\beta$ Glc** (0.900 g, 1.12 mmol, 74%). Calculated for C<sub>25</sub>H<sub>32</sub>N<sub>3</sub>O<sub>10</sub><sup>+</sup> [M-BF<sub>4</sub>]<sup>+</sup>  $m/z$  = 534.2064. Found  $m/z$  = 534.2084; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD):  $\delta$  = 1.94, 1.99 (2  $\times$  s, 3H, OC(O)CH<sub>3</sub>), 2.02–2.06 (m, 6H, 2  $\times$  OC(O)CH<sub>3</sub>), 3.77–3.86 (ddd, 1H, <sup>3</sup>J<sub>H,H</sub> = 10.1, 4.4, 2.0 Hz, glucosyl C<sup>5</sup>H), 4.0–9.44 (m, 7H, N-CH<sub>3</sub>, glucosyl C<sup>6</sup>H<sub>2</sub>, O-CH<sub>2</sub>-CH<sub>2</sub>N), 4.69 (d, 1H, <sup>3</sup>J<sub>H,H</sub> = 7.9 Hz, glucosyl C<sup>1</sup>H), 2.82–2.98 (m, 3H, O-CH<sub>2</sub>-CH<sub>2</sub>N and glucosyl C<sup>2</sup>H), 5.04 (t, 1H, <sup>3</sup>J<sub>H,H</sub> = 9.5 Hz, glucosyl C<sup>4</sup>H), 5.22 (t, 1H,  $J$  = 9.5 Hz, glucosyl C<sup>3</sup>H), 7.53–7.72 (m, 5H, C<sub>ph</sub>H), 8.52 (C<sub>trz</sub>H); <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD):  $\delta$  = 20.57, 20.62, 20.7, (4  $\times$  OC(O)CH<sub>3</sub> [2  $\times$  overlapping]), 38.4 (N-CH<sub>3</sub>), 54.1 (ethylene CH<sub>2</sub>), 61.6 (glucosyl C<sup>6</sup>H<sub>2</sub>), 66.6 (ethylene CH<sub>2</sub>), 68.1 (glucosyl C<sup>4</sup>H), 71.2 (glucosyl C<sup>2</sup>H), 71.9 (glucosyl C<sup>5</sup>H), 72.5 (glucosyl C<sup>3</sup>H), 100.6 (glucosyl C<sup>1</sup>H), 122.0 (C<sub>ph</sub>-trz), 129.2 (C<sub>trz</sub>H), 129.4, 129.8, 132.0 (3  $\times$  C<sub>ph</sub>H), 143.2 (C<sub>trz</sub>-Ph), 169.6, 169.9, 170.0, 170.7 (4  $\times$  C=O).

**4 $\beta$ Gal.** According to the general procedure, **2 $\beta$ Gal** (0.535 g, 1.03 mmol) and Meerwein's reagent (0.165 g, 1.10 mmol) were reacted, yielding **4 $\beta$ Gal** (0.695 g, quant.). Calculated for C<sub>25</sub>H<sub>32</sub>N<sub>3</sub>O<sub>10</sub><sup>+</sup> [M-BF<sub>4</sub>]<sup>+</sup>  $m/z$  = 534.2064. Found  $m/z$  = 534.2070; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.90, 1.95, 2.04, 2.10 (4  $\times$  s, 3H, OC(O)CH<sub>3</sub>), 3.97 (t, 1H, <sup>3</sup>J<sub>H,H</sub> = 6.5 Hz, galactosyl C<sup>5</sup>H), 4.01–16 (m, 2H, galactosyl C<sup>6</sup>H<sub>2</sub>), 4.17–4.39 (m, 5H, ethylene CH<sub>2</sub>, N-CH<sub>3</sub>), 4.62 (d, 1H, <sup>3</sup>J<sub>H,H</sub> = 7.6 Hz, galactosyl C<sup>1</sup>H), 4.76–4.98 (m, 2H, ethylene CH<sub>2</sub>), 5.01 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 10.4, 3.3 Hz, galactosyl C<sup>3</sup>H), 5.09 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 10.4, 7.6 Hz, galactosyl C<sup>2</sup>H), 5.38 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 3.3, 1.1 Hz, galactosyl C<sup>4</sup>H), 7.52–7.72 (m, 5H, C<sub>ph</sub>H), 8.51 (C<sub>trz</sub>H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 20.5, 20.6, 20.7 (4  $\times$  OC(O)CH<sub>3</sub> [2  $\times$  overlapping]), 38.4 (N-CH<sub>3</sub>), 54.1 (ethylene CH<sub>2</sub>), 61.2 (galactosyl C<sup>6</sup>H<sub>2</sub>), 66.2 (ethylene CH<sub>2</sub>), 67.0 (galactosyl C<sup>4</sup>H), 68.7 (galactosyl C<sup>2</sup>H), 70.5 (galactosyl C<sup>3</sup>H), 70.9 (galactosyl C<sup>5</sup>H), 100.9 (galactosyl C<sup>1</sup>H), 122.1 (C<sub>ph</sub>-trz), 129.1 (C<sub>trz</sub>H), 129.4, 129.8, 132.0 (3  $\times$  C<sub>ph</sub>H), 143.3 (C<sub>trz</sub>-Ph), 169.9, 170.1, 170.4, 170.6 (4  $\times$  C=O).

**4 $\alpha$ Man.** According to the general procedure, **2 $\alpha$ Man** (0.720 g, 1.38 mmol) and Meerwein's reagent (0.209 g, 1.41 mmol) were

reacted, yielding **4 $\alpha$ Man** (0.840 g, quant.). Calculated for C<sub>25</sub>H<sub>32</sub>N<sub>3</sub>O<sub>10</sub><sup>+</sup> [M-BF<sub>4</sub>]<sup>+</sup>  $m/z$  = 534.2064. Found  $m/z$  = 534.2069; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.97, 2.02, 2.10, 2.14 (4  $\times$  s, 3H, 4  $\times$  OC(O)CH<sub>3</sub>), 3.87–4.02 (m, 1H, mannosyl C<sup>5</sup>H), 4.01–4.37 (m, 8H, N-CH<sub>3</sub>, mannosyl C<sup>6</sup>H<sub>2</sub> and ethylene CH<sub>2</sub>), 4.84 (d, 1H, <sup>3</sup>J<sub>H,H</sub> = 1.8 Hz, mannosyl C<sup>1</sup>H), 4.93 (app t, 2H, ethylene CH<sub>2</sub>), 5.12 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 3.0, 1.8 Hz, mannosyl C<sup>2</sup>H), 5.13–5.34 (m, 2H, mannosyl C<sup>3</sup>H, C<sup>4</sup>H), 7.51–7.71 (m, 5H, C<sub>ph</sub>H), 8.67 (s, 1H, C<sub>trz</sub>H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 20.71, 20.75, 20.9 (4  $\times$  OC(O)CH<sub>3</sub> [2  $\times$  overlapping]), 38.5 (N-CH<sub>3</sub>), 53.6 (ethylene CH<sub>2</sub>), 62.4 (mannosyl C<sup>6</sup>H<sub>2</sub>), 64.6 (ethylene CH<sub>2</sub>), 65.8 (mannosyl C<sup>4</sup>H), 68.9 (mannosyl C<sup>3</sup>H), 69.0 (mannosyl C<sup>2</sup>H), 69.1 (mannosyl C<sup>5</sup>H), 97.3 (mannosyl C<sup>1</sup>H), 121.9 (C<sub>ph</sub>-trz), 129.0 (C<sub>trz</sub>-Ph), 129.5, 129.7, 132.0 (3  $\times$  C<sub>ph</sub>H), 143.7 (C<sub>trz</sub>-Ph), 169.7, 170.2, 170.3, 170.9 (4  $\times$  C=O).

**General synthesis of iridium complexes.** The relevant triazolium salt (1 equiv.), Ag<sub>2</sub>O (0.5 equiv.) and NMe<sub>4</sub>Cl (1 equiv.) were suspended in dry CH<sub>3</sub>CN (50 mL) and stirred in darkness at room temperature for 18 hours. Crude <sup>1</sup>H NMR analysis showed disappearance of the resonance associated with the triazolium CH. The reaction mixture was filtered through a bed of celite and concentrated under reduced pressure. The residue was dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> and [IrCl<sub>2</sub>Cp\*]<sub>2</sub> (0.37 equiv.) added. The reaction was stirred in darkness at room temperature for 18 hours, before cooling over an ice bath, filtering through a bed of Celite and concentrating under reduced pressure, yielding a crude orange solid. This was purified by gradient flash chromatography (SiO<sub>2</sub>; CH<sub>2</sub>Cl<sub>2</sub>-(CH<sub>2</sub>)<sub>2</sub>CO 0  $\rightarrow$  10%), yielding the product as a yellow solid.

**5 $\alpha$ Man.** According to the general procedure, **3 $\alpha$ Man** (1.346 g, 2.33 mmol), Ag<sub>2</sub>O (0.278 g, 1.20 mmol), NMe<sub>4</sub>Cl (0.254 g, 2.33 mmol) and [IrCl<sub>2</sub>Cp\*]<sub>2</sub> (0.708 g, 0.89 mmol) were reacted, yielding **5 $\alpha$ Man** (0.480 g, 1.07 mmol, 46%). Anal. calc. for C<sub>33</sub>H<sub>42</sub>N<sub>3</sub>O<sub>9</sub>IrCl<sub>2</sub> (887.834 g/mol), C 44.64, H 4.77, N 4.73%. Found C 45.08, H 5.18, N 4.39%; HRMS (ESI<sup>+</sup>) Calculated for C<sub>33</sub>H<sub>42</sub>N<sub>3</sub>O<sub>9</sub>IrCl<sub>2</sub> [M-Cl]<sup>+</sup>  $m/z$  = 852.2233. Found  $m/z$  = 852.2237; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.49 (s, 15H, Cp\*), 2.02, 2.08, 2.13, 2.24 (4  $\times$  s, 3H, OC(O)CH<sub>3</sub>), 3.88 (s, 3H, N-CH<sub>3</sub>), 4.15–4.44 (m, 3H, mannosyl C<sup>6</sup>H<sub>2</sub> and C<sup>5</sup>H), 5.43 (t, 1H, <sup>3</sup>J<sub>H,H</sub> = 9.9 Hz, mannosyl C<sup>4</sup>H), 5.91 (br s, 1H, mannosyl C<sup>2</sup>H), 6.03 (dd, 1H, <sup>3</sup>J<sub>H,H</sub> = 9.8, 3.2 Hz, mannosyl C<sup>3</sup>H), 7.42–7.55 (m, 4H, mannosyl C<sup>1</sup>H, 3  $\times$  C<sub>ph</sub>H), 7.57–7.67 (m, 2H, C<sub>ph</sub>H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.6 (Cp\* CH<sub>3</sub>), 20.7, 20.78, 20.80, 20.9 (4  $\times$  OC(O)CH<sub>3</sub>), 37.8 (N-CH<sub>3</sub>), 62.9 (mannosyl C<sup>6</sup>H<sub>2</sub>), 66.2 (mannosyl C<sup>4</sup>H), 68.6 (mannosyl C<sup>3</sup>H), 69.1 (mannosyl C<sup>2</sup>H), 72.6 (mannosyl C<sup>5</sup>H), 87.2 (mannosyl C<sup>1</sup>H), 88.6 (Cp\* qt), 127.1, 127.9, 130.2, 132.4 (4  $\times$  C<sub>ph</sub>), 149.8 (br 2  $\times$  C<sub>trz</sub>), 169.0, 169.7, 170.0, 170.5 (4  $\times$  OC(O)CH<sub>3</sub>).

**5 $\beta$ Man.** According to the general procedure, **3 $\beta$ Man** (0.280 g, 0.49 mmol), Ag<sub>2</sub>O (0.058 g, 0.25 mmol), NMe<sub>4</sub>Cl (0.054 g, 0.49 mmol) and [IrCl<sub>2</sub>Cp\*]<sub>2</sub> (0.159 g, 0.19 mmol) were reacted, yielding **5 $\beta$ Man** (0.270 g, 0.30 mmol, 62%). Anal. calc. for C<sub>33</sub>H<sub>42</sub>N<sub>3</sub>O<sub>9</sub>IrCl<sub>2</sub>·2(H<sub>2</sub>O) (923.8643 g/mol), C 42.90, H 5.02, N 4.55%. Found C 43.10, H 5.37, N 4.03%; HRMS (ESI<sup>+</sup>) Calculated for C<sub>33</sub>H<sub>42</sub>N<sub>3</sub>O<sub>9</sub>IrCl<sub>2</sub> [M-Cl]<sup>+</sup>  $m/z$  = 852.2233. Found  $m/z$  = 852.2252; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.41 (s, 15H, Cp\*), 2.04, 2.09, 2.25 (3  $\times$  s, 3H, OC(O)CH<sub>3</sub>), 3.75 (s, 3H, N-CH<sub>3</sub>), 4.16–4.40 (m, 3H, mannosyl C<sup>6</sup>H<sub>2</sub>, C<sup>5</sup>H), 5.14–5.28 (m, 1H, mannosyl C<sup>2</sup>H), 5.47 (t, 1H, <sup>3</sup>J<sub>H,H</sub> = 9.9 Hz, mannosyl C<sup>4</sup>H), 5.66 (br s, 1H, mannosyl C<sup>2</sup>H), 7.40–7.51 (m, 3H, C<sub>ph</sub>H), 7.56 (br d, 1H, <sup>3</sup>J<sub>H,H</sub> = 0.6 Hz, mannosyl C<sup>1</sup>H), 7.76 (br s, C<sub>ph</sub>H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.8 (Cp\* CH<sub>3</sub>), 20.6, 20.8, 20.97, 21.04 (4  $\times$  OC(O)CH<sub>3</sub>), 37.8 (N-CH<sub>3</sub>), 62.3 (mannosyl C<sup>6</sup>H<sub>2</sub>), 65.6 (mannosyl C<sup>4</sup>H), 69.4 (mannosyl C<sup>2</sup>H), 71.7 (mannosyl C<sup>3</sup>H), 75.5 (mannosyl C<sup>5</sup>H), 85.6 (mannosyl C<sup>1</sup>H), 88.8 (Cp\* qt), 127.1, 128.2, 130.2, 132.8 (4  $\times$  C<sub>ph</sub>), 148.3 (C<sub>trz</sub>-Ir), 149.3 (C<sub>trz</sub>-Ph), 169.75, 169.82, 169.9, 170.9 (4  $\times$  C=O).

**6 $\beta$ Glc.** According to the general procedure, **4 $\beta$ Glc** (0.845 g, 1.36 mmol), Ag<sub>2</sub>O (0.160 g, 0.69 mmol), NMe<sub>4</sub>Cl (0.149 g, 1.36 mmol) and [IrCl<sub>2</sub>Cp\*]<sub>2</sub> (0.519 g, 0.65 mmol) were reacted, yielding **6 $\beta$ Glc**



(0.412 g, 0.66 mmol, 48%). Anal. calc. for  $C_{35}H_{46}N_3O_{10}IrCl_2 \cdot 2(H_2O)$  (967.917 g/mol), C 43.43, H 5.21, N 4.34%. Found C 43.73, H 5.30, N 3.79%; HRMS (ESI+) Calculated for  $C_{35}H_{46}N_3O_{10}IrCl_2^+ [M-Cl]^+ m/z = 896.2495$ . Found  $m/z = 896.2518$ ;  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta = 1.40$  (s, 15H,  $Cp^* CH_3$ ), 2.00, 2.03, 2.05, 2.09 (4  $\times$  s, 3H,  $OC(O)CH_3$ ), 3.70–3.83 (m, 4H,  $N-CH_3$  and  $C^5H$ ), 4.14 (dd, 1H,  $^3J_{H,H} = 2.4$  Hz,  $^2J_{H,H} = 12.3$  Hz, glucosyl  $C^6HH$ ), 4.22–4.50 (m, 3H, glucosyl  $C^6HH$  and ethylene  $CH_2$ ), 4.71 (br s, 1H, glucosyl  $C^1H$ ), 4.83–5.16 (m, 4H, glucosyl  $C^2H$ ,  $C^4H$ , and ethylene  $CH_2$ ), 5.21 (t, 1H,  $^3J_{H,H} = 9.4$  Hz, glucosyl  $C^3H$ ), 7.35–7.52 (m, 3H,  $C_{ph}H$ ), 7.64–7.75 (m, 2H,  $C_{ph}H$ );  $^{13}C$  NMR (75 MHz,  $CDCl_3$ ):  $\delta = 8.8$  ( $Cp^* CH_3$ ), 20.6, 20.8, 20.9 (4  $\times$   $OC(O)CH_3$ ), 37.1 ( $N-CH_3$ ), 61.9 ( $CH_2$ ), 62.1 ( $CH_2$ ), 68.2 (glucosyl  $C^3H$ ), 68.5 ( $CH_2$ ), 71.4 (glucosyl  $C^2H$ ), 71.8 (glucosyl  $C^5H$ ), 72.9 (glucosyl  $C^4H$ ), 88.2 ( $Cp^* qt$ ), 100.4 (glucosyl  $C^1H$ ), 127.6, 127.9, 129.9, 132.6 (4  $\times$   $C_{ph}$ ), 146.6 ( $C_{trz-Ir}$ ), 149.0 ( $C_{trz-Ph}$ ), 169.3, 169.6, 170.2, 170.6 (4  $\times$   $C=O$ ).

**6 $\beta$ Gal.** According to the general procedure, **4 $\beta$ Gal** (0.500 g, 0.80 mmol),  $Ag_2O$  (0.093 g, 0.40 mmol),  $NMe_4Cl$  (0.087 g, 0.80 mmol) and  $[IrCl_2Cp^*]_2$  (0.236 g, 0.30 mmol) were reacted, yielding **6 $\beta$ Gal** (0.270 g, 0.28 mmol, 36%). Anal. calc. for  $C_{35}H_{46}N_3O_{10}IrCl_2 \cdot (H_2O)$  (949.902 g/mol), C 44.26, H 5.09, N 4.42%. Found C 44.17, H 5.14, N 3.89%; HRMS (ESI+) Calculated for  $C_{35}H_{46}N_3O_{10}IrCl_2^+ [M-Cl]^+ m/z = 896.2495$ . Found  $m/z = 896.2469$ ;  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta = 1.41$  (s, 15H,  $Cp^* CH_3$ ), 1.98, 2.06, 2.07, 2.13 (4  $\times$  s, 3H,  $OC(O)CH_3$ ), 3.74 (s,  $N-CH_3$ ), 3.97 (t, 1H,  $^3J_{H,H} = 6.7$  Hz, galactosyl  $C^5H$ ), 4.14 (d, 2H,  $J = 6.7$  Hz, galactosyl  $C^6H_2$ ), 4.28–4.42 (m, 2H, ethylene  $CH_2$ ), 4.69 (br d, 1H, galactosyl  $C^1H$ ), 4.76–5.23 (br m, 4H, ethylene  $CH_2$  (broad) and galactosyl  $C^2H$ ,  $C^4H$ ), 5.41 (dd, 1H,  $J = 3.3, 1.1$  Hz, galactosyl  $C^3H$ ), 7.39–7.50 (m, 3H,  $C_{ph}H$ ), 7.63–7.78 (m, 2H,  $C_{ph}H$ );  $^{13}C$  NMR (75 MHz,  $CDCl_3$ ):  $\delta = 8.8$  ( $Cp^* CH_3$ ), 20.6, 20.7, 20.8, 21.0 (4  $\times$   $OC(O)CH_3$ ), 37.1 ( $N-CH_3$ ), 61.1 (galactosyl  $C^6H_2$ ), 67.0 (galactosyl  $C^4H$ ), 68.4 (ethylene  $CH_2$ ), 68.9 (galactosyl  $C^2H$ ), 70.7 (galactosyl  $C^3H$ ), 70.9 (galactosyl  $C^5H$ ), 88.2 ( $Cp^* qt$ ), 100.8 (galactosyl  $C^1H$ ), 127.6, 127.9, 129.9, 132.6 (4  $\times$   $C_{ph}$ ), 146.7 ( $C_{trz-Ir}$ ), 149.0 ( $C_{trz-Ph}$ ), 169.4, 170.08, 170.12, 170.4 (4  $\times$   $C=O$ ).

**6 $\alpha$ Man.** According to the general procedure, **4 $\alpha$ Man** (0.500 g, 0.80 mmol),  $Ag_2O$  (0.093 g, 0.40 mmol),  $NMe_4Cl$  (0.087 g, 0.80 mmol) and  $[IrCl_2Cp^*]_2$  (0.236 g, 0.30 mmol) were reacted, yielding **6 $\alpha$ Man** (0.220 g, 0.23 mmol, 30%). Anal. calc. for  $C_{35}H_{46}N_3O_{10}IrCl_2 \cdot (CH_2Cl_2) \cdot 0.5((CH_3)_2CO)$  (961.927 g/mol), C 46.20, H 5.89, N 4.37%. Found C 46.44, H 5.14, N 3.85%; HRMS (ESI+) Calculated for  $C_{35}H_{46}N_3O_{10}IrCl_2^+ [M-Cl]^+ m/z = 896.2495$ . Found  $m/z = 896.2481$ ;  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta = 1.42$  (s, 15H,  $Cp^* CH_3$ ), 1.99, 2.04, 2.13, 2.17 (4  $\times$  s, 3H,  $OC(O)CH_3$ ), 3.77 (s, 3H,  $N-CH_3$ ), 4.00–4.11 (m, 1H, mannosyl  $C^5H$ ), 4.11–4.44 (m, 4H, ethylene  $CH_2$  and mannosyl  $C^6H_2$ ), 4.84 (br s, 1H, mannosyl  $C^1H$ ), 4.93–5.16 (m, 2H, ethylene  $CH_2$ ), 5.18 (br s, 1H, mannosyl  $C^4H$ ), 5.21–5.32 (m, 2H, mannosyl  $C^3H$ ,  $C^2H$ ), 7.40–7.51 (m, 3H,  $C_{ph}H$ ), 7.70–7.86 (m, 2H,  $C_{ph}H$ );  $^{13}C$  NMR (75 MHz,  $CDCl_3$ ):  $\delta = 8.9$  ( $Cp^* CH_3$ ), 20.73, 20.75, 20.9, 21.0 (4  $\times$   $OC(O)CH_3$ ), 37.2 ( $N-CH_3$ ), 54.0 (ethylene  $CH_2$ ), 62.4 (mannosyl  $C^6H_2$ ), 66.1 (ethylene  $CH_2$ ), 66.5 (mannosyl  $C^2H$ ), 68.9 (mannosyl  $C^5H$ ), 69.3 (mannosyl  $C^3H$ ), 88.2 ( $Cp^* qt$ ), 100.0 (mannosyl  $C^1H$ ), 127.5, 127.9, 129.8, 132.7 (4  $\times$   $C_{ph}$ ), 146.9 ( $C_{trz-Ir}$ ), 149.2 ( $C_{trz-Ph}$ ), 169.6, 169.9, 170.3, 170.8 (4  $\times$   $C=O$ ).

**General synthesis of deprotected iridium complexes.** The relevant protected iridium complex **5/6** (0.1 mmol) was dissolved in methanolic hydrochloric acid (0.5 M, 2.5 mL) and stood at room temperature overnight. The solution was cooled to  $-20^\circ C$  and any precipitate filtered. To the filtrate, copious  $Et_2O$  was added and the suspension stored at  $-20^\circ C$  for 1 hour. The product was collected as a pale yellow or orange solid upon filtration.

**7 $\alpha$ Man.** According to the general procedure, protected complex **5 $\alpha$ Man** (0.100 g, 0.11 mmol) was reacted with methanolic hydrochloric acid (0.5 M, 2.5 mL), yielding **7 $\alpha$ Man** (0.052 g,

0.07 mmol, 64%). Anal. calc. for  $C_{25}H_{34}N_3O_5IrCl_2 \cdot 2.5(H_2O)$  (784.722 g/mol), C 39.27, H 5.14, N 5.49%. Found C 39.70, H 5.67, N 5.42%; HRMS (ESI+) Calculated for  $C_{25}H_{34}N_3O_5IrCl_2^+ [M-Cl]^+ m/z = 684.1811$ . Found  $m/z = 684.1793$ ;  $^1H$  NMR (300 MHz,  $CD_3OD$ ):  $\delta = 1.44$  (s, 15H,  $Cp^* CH_3$ ), 3.66–4.01 (m, 7H,  $N-CH_3$ , mannosyl  $C^6H_2$ ,  $C^5H$ ,  $C^4H$ ), 4.26 (br s, 1H, mannosyl  $C^2H$ ), 4.37 (br s, 1H, mannosyl  $C^3H$ ), 6.66 (br s, 1H, mannosyl  $C^1H$ ), 7.41–7.56 (m, 3H,  $C_{ph}H$ ), 7.60–7.73 (m, 2H,  $C_{ph}H$ );  $^{13}C$  NMR (75 Hz,  $CD_3OD$ ):  $\delta = 7.6$  ( $Cp^* CH_3$ ), 36.8 ( $N-CH_3$ ), 61.8 (mannosyl  $C^6H_2$ ), 68.3, 71.0, 71.0, 77.7 (5  $\times$  mannosyl  $CH$ ), 88.8 ( $Cp^* qt$ ), 89.5 (mannosyl  $C^1H$ ), 127.6, 127.7, 129.6, 132.2 (4  $\times$   $C_{ph}$ ), 146.6 ( $C_{trz-Ir}$ ), 148.2 ( $C_{trz-Ph}$ ).

**7 $\beta$ Man.** According to the general procedure, protected complex **5 $\beta$ Man** (0.170 g, 0.19 mmol) was reacted with methanolic hydrochloric acid (0.5 M, 2.5 mL), yielding **7 $\beta$ Man** (0.095 g, 0.13 mmol, 68%). Anal. calc. for  $C_{25}H_{34}N_3O_5IrCl_2 \cdot (H_2O)$  (737.700 g/mol), C 40.70, H 4.92, N 5.70%. Found C 40.65, H 5.12, N 5.43%; HRMS (ESI+) Calculated for  $C_{25}H_{34}N_3O_5IrCl_2^+ [M-Cl]^+ m/z = 684.1811$ . Found  $m/z = 684.1822$ ;  $^1H$  NMR (300 MHz,  $CD_3OD$ ):  $\delta = 1.32$  (s, 15H,  $Cp^* CH_3$ ), 3.61–3.82 (m, 4H, mannosyl  $C^5H$ ,  $C^4H$ ,  $C^3H$ ,  $C^6HH$ ), 4.00 (app d, 1H,  $^3J_{H,H} = 11.3$  Hz, mannosyl  $C^6HH$ ), 4.09 (s, 3H,  $N-CH_3$ ), 4.27 (br s, 1H, mannosyl  $C^2H$ ), 6.03 (br s, 1H mannosyl  $C^1H$ ), 7.49–7.66 (m, 3H,  $C_{ph}H$ ), 7.82–7.97 (m, 2H,  $C_{ph}H$ );  $^{13}C$  NMR (75 MHz,  $CD_3OD$ ):  $\delta = 7.8$  ( $Cp^* CH_3$ ), 37.0 ( $N-CH_3$ ), 61.3 (mannosyl  $C^6H_2$ ), 67.3 (mannosyl  $C^4H$ ), 71.0 (mannosyl  $C^2H$ ), 73.0 (mannosyl  $C^3H$ ), 81.4 (mannosyl  $C^5H$ ), 86.9 (mannosyl  $C^1H$ ), 89.0 ( $Cp^* qt$ ), 127.0, 128.7, 130.3, 131.7 (4  $\times$   $C_{ph}$ ), 146.2 ( $C_{trz-Ir}$ ), 146.9 ( $C_{trz-Ph}$ ).

**8 $\beta$ Glc.** According to the general procedure, protected complex **6 $\beta$ Glc** (0.250 g, 0.27 mmol) was reacted with methanolic hydrochloric acid (0.5 M, 2.5 mL) yielded **8 $\beta$ Glc** (0.042 g, 0.06 mmol, 22%). Anal. calc. for  $C_{27}H_{38}N_3O_6IrCl_2 \cdot (H_2O)$  (781.753 g/mol), C 41.48, H 5.16, N 5.38%. Found C 41.72, H 5.54, N 5.09%; HRMS (ESI+) Calculated for  $C_{27}H_{38}N_3O_6IrCl_2^+ [M-Cl]^+ m/z = 728.2078$ . Found  $m/z = 728.2037$ ;  $^1H$  NMR (300 MHz,  $CD_3OD$ ):  $\delta = 1.41$  (s, 15H,  $Cp^* CH_3$ ), 3.18 (t, 1H,  $^3J_{H,H} = 8.3$  Hz, glucosyl  $C^2H$ ), 3.24–3.41 (m [overlaps with  $CH_3OH$  residual peak], 3H, glucosyl  $C^4H$ ,  $C^2H$ ,  $C^3H$ ), 3.68 (dd, 1H,  $^3J_{H,H} = 5.1$  Hz,  $^2J_{H,H} = 11.9$  Hz, glucosyl  $C^6HH$ ), 3.75–3.99 (m, 4H,  $N-CH_3$  and glucosyl  $C^6HH$ ), 4.25 (br s, 1H, ethylene  $CHH$ ), 4.34–4.54 (m, 2H, ethylene  $CHH$  and glucosyl  $C^1H$  ( $^3J_{H,H} = 7.80$ )), 5.00 (br s [overlaps with  $H_2O$  resonance], 2H, ethylene  $CH_2$ ), 7.40–7.53 (m, 3H,  $C_{ph}H$ ), 7.64–7.76 (m, 2H,  $C_{ph}H$ );  $^{13}C$  NMR (75 MHz,  $CD_3OD$ ):  $\delta = 7.7$  ( $Cp^* CH_3$ ), 36.4 ( $N-CH_3$ ), 53.7 (ethylene  $CH_2$ ), 61.3 (glucosyl  $C^6H_2$ ), 67.7 (ethylene  $CH_2$ ), 70.2 (glucosyl  $C^4H$ ), 73.6 (glucosyl  $C^3H$ ), 76.7 (glucosyl  $C^2H$ ), 76.9 (glucosyl  $C^5H$ ), 88.5 ( $Cp^* qt$ ), 103.1 (glucosyl  $C^1H$ ), 127.5, 127.9, 129.5, 132.4 (4  $\times$   $C_{ph}$ ), 145.9 ( $C_{trz-Ir}$  [determined by HMBC]), 148.1 ( $C_{trz-Ph}$ ).

**8 $\beta$ Gal.** According to the general procedure, protected complex **6 $\beta$ Gal** (0.140 g, 0.15 mmol) was reacted with methanolic hydrochloric acid (0.5 M, 2.5 mL) yielded **8 $\beta$ Gal** (0.053 g, 0.69 mmol, 46%). Anal. calc. for  $C_{27}H_{38}N_3O_6IrCl_2 \cdot 1.5(H_2O)$  (790.761 g/mol), C 41.01, H 5.23, N 5.31%. Found C 40.82, H 5.74, N 5.16%; HRMS (ESI+) Calculated for  $C_{27}H_{38}N_3O_6IrCl_2^+ [M-Cl]^+ m/z = 728.2078$ . Found  $m/z = 728.2071$ ;  $^1H$  NMR (300 MHz,  $CD_3OD$ ):  $\delta = 1.42$  (s, 15H,  $Cp^* CH_3$ ), 3.41–3.61 (m, 3H, galactosyl  $C^5H$ ,  $C^2H$ ,  $C^3H$ ), 3.69–3.91 (m, 6H, galactosyl  $C^6H_2$ , Gal  $C^4H$ ,  $N-CH_3$ ), 4.24 (br s, 1H, ethylene  $CHH$ ), 4.37 (d, 1H,  $^3J_{H,H} = 6.9$  Hz, galactosyl  $C^1H$ ), 4.49 (br s, 1H, ethylene  $CHH$ ), 4.91–5.06 (m [overlaps with  $H_2O$  resonance], 2H, ethylene  $CH_2$ ), 7.39–7.44 (m, 3H,  $C_{ph}H$ ), 7.63–7.72 (m, 2H,  $C_{ph}H$ );  $^{13}C$  NMR (75 MHz,  $CD_3OD$ ):  $\delta = 7.8$  ( $Cp^* CH_3$ ), 36.4 ( $N-CH_3$ ), 53.7 (ethylene  $CH_2$ ), 61.1 (galactosyl  $C^6H_2$ ), 67.8 (ethylene  $CH_2$ ), 68.9 (galactosyl  $C^4H$ ), 70.9 (galactosyl  $C^2H$ ), 73.8 (galactosyl  $C^3H$ ), 75.3 (galactosyl  $C^5H$ ), 88.5 ( $Cp^* qt$ ), 103.8 (galactosyl  $C^1H$ ), 127.5, 127.9, 129.5, 132.4 (4  $\times$   $C_{ph}$ ), 145.6 ( $C_{trz-Ir}$ ), 148.1 ( $C_{trz-Ph}$ ).

**8 $\alpha$ Man.** Yield = 11%. Anal. calc. for  $C_{27}H_{38}N_3O_6IrCl_2 \cdot 2.5(H_2O)$  (808.776 g/mol), C 40.10, H 5.36, N 5.20%. Found C 40.07, H 5.84, N



5.32%; HRMS (ESI+) Calculated for  $C_{27}H_{38}N_3O_5IrCl^+$   $[M-Cl]^+$   $m/z = 728.2078$ . Found  $m/z = 728.2085$ ;  $^1H$  NMR (300 MHz,  $CD_3OD$ ):  $\delta = 1.41$  (s, 15H,  $Cp^* CH_3$ ), 3.43–3.56 (m, 1H, mannosyl  $C^5H$ ), 3.56–3.67 (m, 2H, mannosyl  $C^3H$ ,  $C^4H$ ), 3.68–3.80 (m, 2H, mannosyl  $C^2H$ ,  $C^6HH$ ), 3.81–3.94 (m, 4H,  $N-CH_3$ , mannosyl  $C^6HH$ ), 3.93–4.17 (br m, 1H, ethylene  $CHH$ ), 4.43 (br s, 1H, ethylene  $CHH$ ), 4.82–5.07 (m [overlaps with  $H_2O$  resonance], 3H, mannosyl  $C^1H$  and ethylene  $CH_2$ ), 7.36–7.58 (m, 3H,  $C_{ph}H$ ), 7.59–7.76 (m, 2H,  $C_{ph}H$ );  $^{13}C$  NMR (75 MHz,  $CD_3OD$ )  $\delta$  7.7 ( $Cp^* CH_3$ ), 36.5 ( $N-CH_3$ ), 53.8 (ethylene  $CH_2$ ), 61.6 (mannosyl  $C^6H_2$ ), 65.5 (br, ethylene  $CH_2$ ), 67.0 (mannosyl  $C^4H$ ), 70.5 (mannosyl  $C^3H$ ), 71.2 (mannosyl  $C^2H$ ), 73.7 (mannosyl  $C^5H$ ), 88.4 ( $Cp^* qt$ ), 100.4 (mannosyl  $C^1H$ ), 127.5, 127.8, 129.5, 132.5 ( $4 \times C_{ph}$ ), 145.6 ( $C_{tz}-Ir$  [determined by HMBC]), 148.3 ( $C_{tz}-Ph$  [determined by HMBC]).

## Supporting Information

Supporting Information consisting of supplementary experimental details, crystallographic data, refinement details and further structural analysis, catalytic data, NMR spectra of new compounds, chiral gas chromatograms for *ee* determination, and enzyme inhibition data. CCDC 2142839, 2142842–2142843.

## Acknowledgements

We are very grateful to Dr Matteo Planchestainer and Dr René Pretorius for useful discussions. We thank Mr Konrad Uhlmann, Mr Stefan Weissen, and Dr Julien Furrer for technical assistance. This work was financially supported by a Marie Skłodowska-Curie Individual Fellowship (JPB, Grant 749549 'GLYCONHC'), the European Research Council (Grant CoG 615653), the UK EPSRCs (LD, Grant EP/L015633/1) and a Royal Society of Chemistry Researcher Mobility Grant (JPB). We thank the group of Chemical Crystallography of the University of Bern (Prof P. Macchi) for the X-ray structure solution and the Swiss National Science Foundation (R'equip project 206021\_128724) for co-funding the single crystal X-ray diffractometer at the Departement für Chemie, Biochemie und Pharmazie, Universität Bern. Open access funding provided by Universität Bern.

## Conflict of Interest

The authors declare no conflict of interest.

## Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

**Keywords:** aqueous hydrogenation · carbohydrates · iridium · ligand effects · N-heterocyclic carbene

[1] T. Wang, X. Han, F. Zhong, W. Yao, Y. Lu, *Acc. Chem. Res.* **2016**, *49*, 1369–1378.

- [2] X. Liu, S. Dong, L. Lin, X. Feng, *Chin. J. Chem.* **2018**, *36*, 791–797.  
 [3] A. S. Henderson, J. F. Bower, M. C. Galan, *Org. Biomol. Chem.* **2016**, *14*, 4008–4017.  
 [4] S. Castellón, C. Claver, Y. Díaz, *Chem. Soc. Rev.* **2005**, *34*, 702.  
 [5] S. Woodward, M. Diéguez, O. Pàmies, *Coord. Chem. Rev.* **2010**, *254*, 2007–2030.  
 [6] M. Diéguez, O. Pàmies, A. Ruiz, S. Castellón, C. Claver, *Tetrahedron: Asymmetry* **2000**, *11*, 4701–4708.  
 [7] K. Yonehara, K. Ohe, S. Uemura, *J. Org. Chem.* **1999**, *64*, 9381–9385.  
 [8] M. Diéguez, O. Pàmies, A. Ruiz, S. Castellón, C. Claver, *Chem. A Eur. J.* **2001**, *7*, 3086–3094.  
 [9] M. Diéguez, J. Mazuela, O. Pàmies, J. J. Verendel, P. G. Andersson, *J. Am. Chem. Soc.* **2008**, *130*, 7208–7209.  
 [10] J. Margalef, O. Pàmies, M. Diéguez, *Chem. A Eur. J.* **2017**, *23*, 813–822.  
 [11] W. Zhao, V. Ferro, M. V. Baker, *Coord. Chem. Rev.* **2017**, *339*, 1–16.  
 [12] K. J. Kilpin, S. Crot, T. Riedel, J. A. Kitchen, P. J. Dyson, *Dalton Trans.* **2014**, *43*, 1443–1448.  
 [13] B. K. Keitz, R. H. Grubbs, *Organometallics* **2010**, *29*, 403–408.  
 [14] R. Pretorius, J. Olguín, M. Albrecht, *Inorg. Chem.* **2017**, *56*, 12410–12420.  
 [15] J.-H. Li, W.-J. Liu, Y.-X. Xie, *J. Org. Chem.* **2005**, *70*, 5409–5412.  
 [16] Y. Imanaka, H. Hashimoto, I. Kinoshita, T. Nishioka, *Chem. Lett.* **2014**, *43*, 687–689.  
 [17] C. C. Yang, P. S. Lin, F. C. Liu, I. J. B. Lin, G. H. Lee, S. M. Peng, *Organometallics* **2010**, *29*, 5959–5971.  
 [18] A. S. Henderson, J. F. Bower, M. C. Galan, *Org. Biomol. Chem.* **2014**, *12*, 9180–9183.  
 [19] A. S. Henderson, J. F. Bower, M. C. Galan, *Org. Biomol. Chem.* **2020**, *18*, 3012–3016.  
 [20] J. P. Byrne, P. Musembi, M. Albrecht, *Dalton Trans.* **2019**, *48*, 11838–11847.  
 [21] A. Fernandes, B. Royo, *ChemCatChem* **2017**, *9*, 3912–3917.  
 [22] Y. Wei, D. Xue, Q. Lei, C. Wang, J. Xiao, *Green Chem.* **2013**, *15*, 629–634.  
 [23] M. Martínez-Calvo, J. L. Mascareñas, *Coord. Chem. Rev.* **2018**, *359*, 57–79.  
 [24] A. L. E. Larsson, B. A. Persson, J. E. Bäckvall, *Angew. Chem. Int. Ed. Engl.* **1997**, *36*, 1211–1212.  
 [25] R. M. Haak, F. Berthiol, T. Jerphagnon, A. J. A. Gayet, C. Tarabiono, C. P. Postema, V. Ritleng, M. Pfeffer, D. B. Janssen, A. J. Minnaard, B. L. Feringa, J. G. De Vries, *J. Am. Chem. Soc.* **2008**, *130*, 13508–13509.  
 [26] F. G. Mutti, A. Orthaber, J. H. Schrittwieser, J. G. D. Vries, R. Pietschnig, W. Kroutil, *Chem. Commun.* **2010**, *46*, 8046–8048.  
 [27] S. Infante-Tadeo, V. Rodríguez-Fanjul, A. Habtemariam, A. M. Pizarro, *Chem. Sci.* **2021**, *12*, 9287–9297.  
 [28] R. V. Maaskant, S. Chordia, G. Roelfes, *ChemCatChem* **2021**, *13*, 1607–1613.  
 [29] S. Bose, A. H. Ngo, L. H. Do, *J. Am. Chem. Soc.* **2017**, *139*, 8792–8795.  
 [30] V. Köhler, Y. M. Wilson, M. Dürrenberger, D. Ghislieri, E. Churakova, T. Quinto, L. Knörr, D. Häussinger, F. Hollmann, N. J. Turner, T. R. Ward, *Nat. Chem.* **2013**, *5*, 93–99.  
 [31] F. Schwizer, Y. Okamoto, T. Heinisch, Y. Gu, M. M. Pellizzoni, V. Lebrun, R. Reuter, V. Köhler, J. C. Lewis, T. R. Ward, *Chem. Rev.* **2018**, *118*, 142–231.  
 [32] H. M. Key, P. Dydio, D. S. Clark, J. F. Hartwig, *Nature* **2016**, *534*, 534–537.  
 [33] L. L. Rossi, A. Basu, *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3596–3599.  
 [34] S. Dedola, D. L. Hughes, S. A. Nepogodiev, M. Rejzek, R. A. Field, *Carbohydr. Res.* **2010**, *345*, 1123–1134.  
 [35] K. L. Cosgrove, P. V. Bernhardt, B. P. Ross, R. P. McGeary, *Aust. J. Chem.* **2006**, *59*, 473.  
 [36] H. Paulsen, Z. Györgydeák, M. Friedmann, *Chem. Ber.* **1974**, *107*, 1568–1578.  
 [37] M. Farrell, J. Zhou, P. V. Murphy, *Chem. A Eur. J.* **2013**, *19*, 14836–14851.  
 [38] W. Hayes, H. M. Osborn, S. D. Osborne, R. A. Rastall, B. Romagnoli, *Tetrahedron* **2003**, *59*, 7983–7996.  
 [39] C. Kieburg, K. Sadalpure, T. K. Lindhorst, *Eur. J. Org. Chem.* **2000**, *2000*, 2035–2040.  
 [40] L. Gu, P. G. Luo, H. Wang, M. J. Meziani, Y. Lin, L. M. Veca, L. Cao, F. Lu, X. Wang, R. A. Quinn, W. Wang, P. Zhang, S. Lacher, Y.-P. Sun, *Biomacromolecules* **2008**, *9*, 2408–2418.  
 [41] S. Lal, S. Díez-González, *J. Org. Chem.* **2011**, *76*, 2367–2373.  
 [42] A. Petronilho, M. Rahman, J. A. Woods, H. Al-Sayyed, H. Müller-Bunz, J. M. Don MacElroy, S. Bernhard, M. Albrecht, *Dalton Trans.* **2012**, *41*, 13074.  
 [43] Determined at 278 K (300 MHz). The minimum value of  $T_1$  could not be determined accurately because of the freezing point of water.  
 [44] R. H. Crabtree, *Acc. Chem. Res.* **1990**, *23*, 95–101.

- [45] G. E. Dobereiner, A. Nova, N. D. Schley, N. Hazari, S. J. Miller, O. Eisenstein, R. H. Crabtree, *J. Am. Chem. Soc.* **2011**, *133*, 7547–7562.
- [46] K. F. Donnelly, R. Lalrempuia, H. Müller-Bunz, M. Albrecht, *Organometallics* **2012**, *31*, 8414–8419.
- [47] R. Corberán, M. Sanaú, E. Peris, *J. Am. Chem. Soc.* **2006**, *128*, 3974–3979.
- [48] A. Mollar-Cuni, J. P. Byrne, P. Borja, C. Vicent, M. Albrecht, J. A. Mata, *ChemCatChem* **2020**, *12*, 3746–3752.
- [49] S. Ogo, T. Abura, Y. Watanabe, *Organometallics* **2002**, *21*, 2964–2969.
- [50] M. T. Reetz, T. Neugebauer, *Angew. Chem. Int. Ed.* **1999**, *38*, 179–181; *Angew. Chem.* **1999**, *111*, 134–137.
- [51] M. Guitet, P. Zhang, F. Marcelo, C. Tugny, J. Jiménez-Barbero, O. Buriez, C. Amatore, V. Mouriès-Mansuy, J. P. Goddard, L. Fensterbank, Y. Zhang, S. Roland, M. Ménand, M. Sollogoub, *Angew. Chem. Int. Ed.* **2013**, *52*, 7213–7218; *Angew. Chem.* **2013**, *125*, 7354–7359.
- [52] J. F. Moya, C. Rosales, I. Fernández, N. Khiar, *Org. Biomol. Chem.* **2017**, *15*, 5772–5780.
- [53] M. Coll, O. Pàmies, M. Diéguez, *Adv. Synth. Catal.* **2014**, *356*, 2293–2302.
- [54] S. Horn, C. Gandolfi, M. Albrecht, *Eur. J. Inorg. Chem.* **2011**, *2011*, 2863–2868.
- [55] N. Hassan, T. H. Nguyen, M. Intanon, L. D. Kori, B. K. C. Patel, D. Haltrich, C. Divne, T. C. Tan, *Appl. Microbiol. Biotechnol.* **2014**, *99*, 1731–1744.
- [56] Dialysis of GH1 enzyme into buffers in the pH range where 7βGal gave the best yields of 1-phenylethanol (pH 3–5) resulted in irreversible protein precipitation and denaturing.
- [57] S. Mandal, R. Das, P. Gupta, B. Mukhopadhyay, *Tetrahedron Lett.* **2012**, *53*, 3915–3918.
- [58] A. Bernardi, J. Jiménez-Barbero, A. Casnati, C. De Castro, T. Darbre, F. Fieschi, J. Finne, H. Funken, K.-E. Jaeger, M. Lahmann, T. K. Lindhorst, M. Marradi, P. Messner, A. Molinaro, P. V. Murphy, C. Nativi, S. Oscarson, S. Penadés, F. Peri, R. J. Pieters, O. Renaudet, J.-L. Reymond, B. Richichi, J. Rojo, F. Sansone, C. Schäffer, W. B. Turnbull, T. Velasco-Torrijos, S. Vidal, S. Vincent, T. Wennekes, H. Zuilhof, A. Imberty, *Chem. Soc. Rev.* **2013**, *42*, 4709–4727.
- [59] C. White, A. Yates, P. M. Maitlis, D. M. Heinekey, John Wiley & Sons, Ltd, **2007**, pp. 228–234.

---

Manuscript received: January 19, 2022  
Revised manuscript received: February 23, 2022  
Accepted manuscript online: February 23, 2022  
Version of record online: March 11, 2022